Antitumor effects of a selenium heteropoly complex in K562 cells.
The aim of this study was to investigate the anti-tumor effects and mechanism of the selenium heteropoly compound (C(2)H(10)N(2))(5)(NH(4))(4)H(2)[Se(2)W(10)V(8)O(62)].9H(2)O (SeWV) in K562 cells. The results showed that 0.32-10.15 x 10(-3) mmol/l SeWV could significantly inhibit the proliferation of K562 cells in vitro, as determined by the MTT assay, with IC(50) values of 3.07 and 2.69 x 10(-3) mmol/l after 48 and 72 h of treatment with SeWV, respectively. Studies of the cell cycle indicated that SeWV could induce K562 cells gathered in the G(2)/M phase upon treatment for 24 and 48 h, and a significant sub-G1 peak was evident at 0.32 and 2.54 x 10(-3) mmol/l after treatment for 24 h. Morphological observations revealed typical apoptotic features. SeWV caused the accumulation of Ca(2+), Mg(2+) and ROS, and the reduction of pH and mitochondrial membrane potential (MMP) in K562 cells as evidenced by confocal laser scanning microscopy. Experiments also showed that the expression of Bcl-2 was significantly inhibited, but Bax was increased by SeWVat 5.07 x 10(-3) mmol/l. Additionally, the content of cytochrome-C was increased after treatment for 24 h. The experiment implied that SeWV had anti-tumor activity and that its mechanism was partially attributable to the induction of cell cycle distribution and apoptosis that was induced by a change in intracellular ion homeostasis.
Jun-Ying
Yang
Y
Key Laboratory for Cell Differentiation Regulation, College of Life Sciences, Henan Normal University, Xinxiang 453007, Henan, PR China. Junyingyang@yahoo.com.cn
Cun-Shuan
Xu
X
D000970:Antineoplastic Agents / Q000494:pharmacology*; D017209:Apoptosis / Q000187:drug effects; D002118:Calcium / Q000378:metabolism; D002453:Cell Cycle / Q000187:drug effects; D049109:Cell Proliferation / Q000187:drug effects; D045304:Cytochromes c / Q000032:analysis; D006801:Humans; D020014:K562 Cells; D008274:Magnesium / Q000378:metabolism; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000032:analysis; D018036:Selenium Compounds / Q000494:pharmacology*
C541881:(C(2)H(10)N(2))(5)(NH(4))(4)H(2)(Se(2)W(10)V(8)O(62)).9H(2)O; D000970:Antineoplastic Agents; D019253:Proto-Oncogene Proteins c-bcl-2; D018036:Selenium Compounds; D045304:Cytochromes c; D008274:Magnesium; D002118:Calcium